Guide for Authors
Overview
In addition to general articles on clinical aspects of diabetes mellitus,
Diabetes and Metabolic Syndrome: Clinical
Research and Reviews also presents articles on basic research in all areas of diabetes and the metabolic syndrome. Topics include
prevention, diagnosis, pathogenesis, clinical management of diabetes and all its complications, including neuropathy, retinopathy, nephropathy,
peripheral vascular disease, foot problems (amongst others), as well as atherosclerotic cardiovascular disease. All aspects of disorders
associated with the metabolic syndrome with a special emphasis on clinical aspects (prevalence, pathogenesis, risk factors management
and prevention, etc.) of comorbid conditions such as hypertension, obesity, dyslipidemias and atherosclerotic cardiovascular disease
are also of relevance to the journal.
Diabetes and Metabolic Syndrome: Clinical Research and Reviews also publishes papers on
the general pathogenesis and prevention of diabetes.
Criteria for initial considerations for papers submitted will be originality,
statistical rigour, and relevance to the aims of the journal. All manuscripts of interest will be subjected to the process of peer review.
Initially all submissions are reviewed internally by members of the Editorial Board and all submissions which pass this stage are then
subjected to an external peer-review process. Please include names and contact details for six individuals as suggested reviewers for
the manuscript, for use at the Editors' discretion.
Journal Principles
All manuscripts submitted to
Diabetes and
Metabolic Syndrome: Clinical Research and Reviews should report original research not previously published or being considered for
publication elsewhere, make explicit any conflict of interest, identify sources of funding and generally be of a high ethical standard.
Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may
be edited to improve clarity and expression. Submission of a paper to
Diabetes and Metabolic Syndrome: Clinical Research and Reviews
is understood to imply that it has not previously been published and that it is not being considered for publication elsewhere.
Ethics
Work on human beings that is submitted to the journal should comply with the principles laid down in the Declaration of Helsinki "Recommendations
guiding physicians in biomedical research involving human subjects", adopted by the 18th World Medical Assembly, Helsinki, Finland, June
1964 (and its successive amendments). The manuscript should contain a statement that the work has been approved by the appropriate ethical
committees related to the institution(s) in which it was performed. Studies involving experiments with animals must state that their
care was in accordance with institution guidelines.
Patients and Study Participants
Studies on patients or volunteers
require ethics committee approval and informed consent which should be documented in your paper.
Patients have a right to privacy.
Therefore identifying information, including patient's photographs, pedigree, images, names, initials, or hospital numbers, should not
be included in the submissions unless the information is essential for scientific purposes and written informed consent has been obtained
for publication in print and electronic form from the patient (or parent, guardian or next of kin ). If such consent is made subject
to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to the journal on request.
Even where consent has been given, identifying details should be omitted if they are not essential. Complete anonymity is difficult to
achieve. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics
are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific
meaning and editors should so note.
Clinical Trials
All randomised controlled trials submitted to
Diabetes and Metabolic
Syndrome: Clinical Research and Reviews whose primary purpose is to affect clinical practice (phase 3 trials) must be registered
in accordance with the principles outlined by the International Committee of Medical Journal Editors (ICMJE;
http://www.icmje.org/).
ICJME-approved registries currently include the following: 'ClinicalTrials.gov'; '
www.ISRCTN.org'; '
www.actr.org.au';
'
www.umin.ac.jp'; and '
www.trialregister.nl'. Please include the unique trial number and registry name on manuscript
submission.
Conflict of Interest
Authors are required to disclose commercial or similar relationships to products or companies
mentioned in or related to the subject matter of the article being submitted. Sources of funding for the article should be acknowledged
in a footnote on the title page. Affiliations of authors should include corporate appointments relating to or in connection with products
or companies mentioned in the article, or otherwise bearing on the subject matter thereof. Other pertinent financial relationships, such
as consultancies, stock ownership or other equity interests or patent-licensing arrangements, should be disclosed to the Editor-in-Chief
in the cover letter at the time of submission. Such relationships may be disclosed in the Journal at the discretion of the Editor-in-Chief.
Article Types
i. Editorials are either written or commissioned by the Editors and should not exceed 1000 words (not including
a maximum of 20 references; one small figure can be included).
ii. Commentaries (1000 words not including a maximum of 20 references
and one small figure) offer a stimulating, journalistic and accessible insight into issues of common interest. They are usually commissioned
by the Editors but unsolicited articles will be considered. Debates comprise two commentaries of opposing or contrasting opinion written
by two different groups of authors. Controversial opinions are welcomed as long as they are set in the context of the generally accepted
view.
iii. Original Research Articles should be a maximum of 5000 words. The word limit includes a maximum of five figures or tables
with legends, but does not include up to 50 references and an abstract of up to 200 words structured according to Aims, Methods, Results,
Conclusions and Keywords. Divide the manuscript into the following sections: Title Page; Structured Abstract; Introduction; Subjects,
Materials and Methods; Results; Discussion; Acknowledgements; References; figures and tables with legends.
iv. Brief Reports should
not exceed 1000 words, including a summary of no more than 50 words (but not including up to 20 references) and may be a preliminary
report of work completed, a final report or an observation not requiring a lengthy write-up.
v. Review articles should be a maximum
of 5000 words, including a summary of no more than 100 words (not including up to 75 references) with subheadings in the text to highlight
the content of different sections. Reviews are generally commissioned by the Editors but unsolicited articles will be considered.
vi. Letters to the Editor should be no more than 400 words.
Manuscript Submission
Manuscripts may be submitted online
or directly to the Editor-in-Chief by e-mail or traditional mail.
Please submit manuscripts online at
http://ees.elsevier.com/dmscrr/
and the instructions on the site should be followed closely. Authors can track manuscript progress to final decision. Reviewers can download
manuscripts and submit their reports to the Editors.
For those who cannot submit online, manuscripts should be typewritten, double-spaced,
using a standard sized typeface and margins of at least one inch. Place insert two carriage returns after every element, such as title,
headings, paragraphs, and figure and table callouts. Please submit with electronic files to the Editor-in-Chief:
Dr S.M. Sadikot
50, Manoel Gonsalves Rd.,
Bandra (W),
Mumbai 400050
India
Phone: +919820045859
E-mail:
journaldms@gmail.com
(Alternative email:
smsadikot@gmail.com)
Title Page
On the title page, include title; subtitle (if any);
first name, middle initial, and last names of each author, with academic degrees; name of Department(s) and Institution(s) to which the
work should be attributed; name and address of author to whom requests for reprints should be sent. The address, telephone and fax numbers
of the person responsible for negotiations concerning the manuscripts should be listed separately and clearly labelled as such. Authors
will be required to sign a statement conferring the manuscript copyright to
Diabetes and Metabolic Syndrome: Clinical Research and
Reviews.
Abstract and Keywords
A structured abstract of 100 to 250 words for articles (including Reviews), or 50
to 100 words for Brief Communications, should be provided. It should cover the main factual points, including statements of the problem,
methods, results, and conclusions. The abstract should be accompanied by a list of three to five keywords for indexing purposes.
Main Text
Headings and subheadings should be provided in the Methods and Results sections, and where appropriate in the discussion.
Please keep the text clear, concise and free of jargon.
Abbreviations, Numbers and SI Units
Authors should limit the
use of abbreviations. Terms which are mentioned frequently may be abbreviated but only if this does not detract from reader comprehension.
The abbreviation should be defined after the first use of the term.
Measurements of length, height, weight and volume should be
reported in metric units. Temperatures should be given in degrees Celsius and blood pressures in millimetres of mercury or kPa with the
alternative unit in parentheses. All other measurements including laboratory measurement should be reported in the metric system in terms
of the International System of Units (SI).
Drug Names
Generic names should be used. Proprietary names may be given (parenthetically)
with the first use of the generic name.
References
References should be numbered consecutively (with square brackets)
as they appear in the text. The reference list should be in the form shown by the three examples below.
Examples:
[1] The F DECODE
Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
[2] J.L. Chiasson, R. Gomis, M. Hanefeld, R.G. Josse, A. Karasik, M. Laakso. The STOP-NIDDM trial: an international study on the efficacy
of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and
preliminary screening data. Diabetes Care 1998;21:1720-5.
[3] R.E. Pratley, C. Weyer. The role of impaired early insulin secretion
in the pathogenesis of type II diabetes mellitus. Diabetologia 2001;44:929-45.
Please note that all authors should be listed when
three or fewer; when four or more, list only the first three and add et al. Do not include references to personal communications, unpublished
data or manuscripts either in preparation or submitted for publication. If essential, such material may be incorporated into the appropriate
place in the text. Titles of journals should be abbreviated according to MEDLINE (National Library of Medicine). Recheck references in
the text against the reference list before your manuscript is accepted. The accuracy of references is the responsibility of the author.
Tables
Tables should be numbered consecutively with Arabic numerals. Provide a short descriptive heading and explanation
above each table with a legend. Symbols for units should be confined to column headings. Abbreviations should be kept to a minimum, and
when used, explained fully.
Figures
Figures must be suitable for high-quality reproduction. Lettering should be complete,
of professional quality, and of a size appropriate to that of the illustration or drawing, with the necessary reduction in size taken
into account. If, together with your accepted article, you submit usable colour figures, Elsevier will ensure that these figures appear
free-of-charge in colour in the electronic version of your accepted article. Colour illustrations can only be included in print if the
additional cost of reproduction is contributed by the author: you will receive information regarding the costs from Elsevier after receipt
of your accepted article. Please go to
http://ees.elsevier.com/dmscrr and click on the Artwork Guidelines.
Supplementary
Files
Authors may submit additional supportive applications, movies, animation sequences, high-resolution images, background
datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article
in Elsevier web products, including ScienceDirect:
http://www.sciencedirect.com. In order to ensure that your submitted
material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material
in electronic format together with the article and supply a concise and descriptive caption for each file.
Language
The
language of the journal is English. Upon request, Elsevier will direct authors to an agent who can check and improve the English of their
paper (prior to submission). Please contact
authorsupport@elsevier.com for further information.
Publisher Services
Proofs will be sent to the authors for careful checking. Corrected proofs should be returned to the publisher within stated deadlines.
Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible. Therefore,
it is important to ensure that all of your corrections are sent back to us in one communication. Subsequent corrections will not be possible,
so please ensure your communication is complete.
Fast-track Publication: The journal aims for prompt publication of all accepted
papers. Submissions containing new and particularly important data may be fast-tracked for peer review and publication; this is a limited
facility and is strictly at the discretion of the Editors.
Page Charges are not made.
Offprints/Reprints. The corresponding author,
at no cost, will be provided with a PDF file of the article. The PDF file is a watermarked version of the published article and includes
a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Paper offprints can be ordered
by the authors. An order form with prices will be sent to the corresponding author.
Special Subject Repositories
Certain repositories
such as PubMed Central ('PMC') are authorized under special arrangement with Elsevier to process and post certain articles. The following
agreements have been established for authors whose articles have been accepted for publication in an Elsevier journal and whose underlying
research is supported by one of the following funding bodies:
o National Institutes of Health: Elsevier will send a version of the
author's accepted manuscript that includes author revisions following peer-review for public access posting 12 months after final publication.
Because the NIH 'Public Access' policy is voluntary, authors may elect not to deposit such articles in PMC. If you wish to 'opt out'
and not deposit to PMC, you may indicate this by sending an e-mail to
NIHauthorrequest@elsevier.com. More information
regarding the agreement between Elsevier and the National Institutes of Health can be found at
http://www.elsevier.com/wps/find/authorshome.authors/nihauthorrequest
o The Wellcome Trust: Elsevier will send to PMC the version of the author's manuscript that reflects all author-agreed changes
including those made post peer review, for public access posting immediately after final publication. Authors are required to initially
subsidize their manuscript with fees reimbursed by the Wellcome Trust. Wellcome Trust authors, whose manuscripts are subsidized, will
have the corresponding articles made free to non-subscribers on ScienceDirect www.sciencedirect.com and Elsevier's electronic publishing
platforms. More information regarding the agreement between Elsevier and The Wellcome Trust can be found at
http://www.elsevier.com/wps/find/authorshome.authors/wellcometrustauthors
